Critical Diagnostics Release: Cardiac Biomarker ST2 Proves Far Superior to Galectin-3 In A Head-to-Head Study
9/30/2013 11:05:22 AM
SAN DIEGO--(BUSINESS WIRE)--Critical Diagnostics announced today that the study, “Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. Galectin-3”, recently published online in JACC (the Journal of the American College of Cardiology) comparing the company’s novel cardiac biomarker ST2 to Galectin-3 (Gal-3), a biomarker from BG Medicine (NASDAQ: BGMD), found ST2 to be superior.
Help employers find you! Check out all the jobs and post your resume.
comments powered by